A Post Authorization Registry Study of Participants Treated With LEQEMBI
Key facts
- Where
- Calgary, Edmonton, Gatineau, Greenfield Park, Kingston, London, Mississauga, Montreal, Ottawa, Peterborough, Québec, Toronto, Vancouver, and Victoria, CanadaSee the 17 sites
Where in Canada
- University of Calgary - Hotchkiss Brain InstituteCalgary, CanadaNot yet recruiting
- University of Alberta, Geriatric DivisionEdmonton, CanadaNot yet recruiting
- Clinique Neuro-OutaouaisGatineau, CanadaNot yet recruiting
- MOCAGreenfield Park, CanadaTaking people
- Kingston HHC (Queen University)Kingston, CanadaNot yet recruiting
- Parkwood Hospital - LondonLondon, CanadaNot yet recruiting
- Trillium HospitalMississauga, CanadaNot yet recruiting
- IUGMMontreal, CanadaNot yet recruiting
- McGill University, Douglas Mental HealthMontreal, CanadaNot yet recruiting
- Bruyère InstituteOttawa, CanadaNot yet recruiting
- Kawartha CenterPeterborough, CanadaTaking people
- CHU de Québec-Université Laval Research CenterQuébec, CanadaNot yet recruiting
- Sunnybrook HospitalToronto, CanadaNot yet recruiting
- Toronto Memory ProgramToronto, CanadaTaking people
- Toronto Western HospitalToronto, CanadaNot yet recruiting
- University of British Columbia - CARDVancouver, CanadaNot yet recruiting
- UBC Victoria - Neil and Susan Manning Cognitive Health InitiativeVictoria, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eisai Limited
- Trial code
- NCT07762092
- Record updated
- 5 November 2026
- Original description
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy [CAA]).Read full original descriptionShow less
Post Authorization Registry Study of Patients Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy [CAA]).
The secondary purpose of this study is,
To describe progression to the next stage of Alzheimer's Disease (AD), stratified by ARIA and intracerebral hemorrhage greater than 1 cm.
To describe previously unknown adverse events related to the long-term safety of LEQEMBI in routine clinical practice, which were not identified in clinical development, as assessed by serious suspected adverse reactions, adverse reactions leading to discontinuation of LEQEMBI treatment, and deaths that occur within 30 days of discontinuation of LEQEMBI treatment (regardless of causality).
To describe drug utilization of LEQEMBI and to assess the effectiveness of risk minimization measures in routine clinical practice.
Inclusion: Participants with Alzheimer's Disease who are prescribed LEQEMBI in Canada.
Exclusion: None.